These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 23001453)

  • 1. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
    Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
    Yang J; Zhao HD; Tan J; Ding YL; Gu ZQ; Zou JJ
    Pharmazie; 2013 Mar; 68(3):183-6. PubMed ID: 23556336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY
    Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population.
    Xie X; Ma YT; Yang YN; Li XM; Ma X; Fu ZY; Zheng YY; Chen BD; Liu F
    PLoS One; 2013; 8(3):e59344. PubMed ID: 23555019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention.
    Liu Y; Liu N; Li W; Shao H; Zhi H; Li J
    Pharmacology; 2013; 91(3-4):165-72. PubMed ID: 23429358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
    Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the use of amlodipine with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention.
    Liu XQ; Lin S; Qiu LL; Lin L; Zhao YY; Xu HM; Zhang J; Zou JJ
    Pharmazie; 2014 Nov; 69(11):814-7. PubMed ID: 25985576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
    Luo Y; Zhao YT; Verdo A; Qi WG; Zhang DF; Hu B
    J Int Med Res; 2011; 39(5):2012-9. PubMed ID: 22118006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
    Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS
    JAMA; 2010 Oct; 304(16):1821-30. PubMed ID: 20978260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
    Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
    Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efffect of the ABCC3 -211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention.
    Zou JJ; Fan HW; Chen SL; Tan J; He BS; Xie HG
    Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):504-9. PubMed ID: 23692149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of clopidogrel.
    O'Connor SA; Hulot JS; Silvain J; Cayla G; Montalescot G; Collet JP
    Curr Pharm Des; 2012; 18(33):5309-27. PubMed ID: 22724417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.